logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10709747 B1

PDFFull Text
Date of Patent:
Jul. 14, 2020

Filed:

Jan. 11, 2019

Encapsulated cannabinoid formulations for oral delivery

Applicant:

Nutrae, Llc, Sarasota, FL (US);

Inventors:

Jacqueline L. Salm, Tampa, FL (US);

Christopher G. Witowski, Tampa, FL (US);

Assignee:

NUTRAE, LLC, Sarasota, FL (US);

Attorneys:

Dickinson Wright PLLC

Kristopher Lance Anderson

Primary Examiner:

Michael Barker

Int. Cl.
CPC ...
A61K 36/00 (2006.01); A61K 36/185 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 31/352 (2006.01); A23L 33/105 (2016.01); A23L 2/56 (2006.01); A61K 9/107 (2006.01); A61K 47/10 (2017.01); A61K 9/70 (2006.01); A61K 31/05 (2006.01); A61K 31/192 (2006.01);
U.S. Cl.
CPC ...
A61K 36/185 (2013.01); A23L 2/56 (2013.01); A23L 33/105 (2016.08); A61K 9/006 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0073 (2013.01); A61K 9/1075 (2013.01); A61K 9/7084 (2013.01); A61K 31/352 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A23V 2002/00 (2013.01); A23V 2200/242 (2013.01); A23V 2250/2132 (2013.01); A61K 31/05 (2013.01); A61K 31/192 (2013.01);
Abstract

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. These preparations demonstrates the viability of sublingual, buccal, or oral delivery using an aqueous-based encapsulation method, including as a beverage or drink.

Find Patent Forward Citations

Loading…